Open AccessDupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis
Author(s) -
Kita Kanako,
Imai Yasutomo,
Nagai Makoto,
Natsuaki Masaru,
Kanazawa Nobuo
Publication year - 2023
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12282
Subject(s) - atopic dermatitis , dupilumab , biomarker , medicine , eczema area and severity index , immunology , immunoglobulin e , stimulation , antibody , biology , biochemistry
Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.